Pay Bill Online
DRUGS APPROVED FROM COMPLETED STUDIES
Below are some research studies that NORI has participated in that have received FDA Approval
Beovu
- FDA approved for treatment of wet age-related macular degeneration in October 2019.
- Beovu is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy
Ozurdex
NORI participated in 1 large Ozurdex® BRVO and CRVO trial from 2004 to 2009
- FDA approved for treatment of Macular Edema associated with Retinal Vein Occlusion June 2009
NORI has participated in 2 large Ozurdex® DME trials from 2004 to present
- Ozurdex® has been submitted to the FDA for approval and is expected to be approved for treatment of DME in the near future
Jetrea
NORI has participated in 2 Jetrea/ocriplamin trials from 2007 to 2009
- FDA approved for treatment of Vitreomacular Adhesion in October 2012
Eylea
NORI has participated in a total of 6 Wet AMD aflibercept trials from 2006 to present
- FDA approved for treatment of Wet AMD November 2011
NORI has participated in 2 Diabetic Macular Edema aflibercept trials from 2008 to 2011
- Expected to be FDA approved for treatment of DME in the near future
NORI has participated in 2 Diabetic Macular Edema aflibercept trials from 2008 to 2011
- FDA approved for treatment of Macular Edema associated with CRVO in September 2012
Lucentis
NORI participated in a total of 9 Wet AMD ranibizumab trials beginning in 2003 until 2012
- FDA approved for treatment of Wet AMD June 2006
- Higher success profile than Macugen®
- NORI was the only clinical research site in Southwest Florida that participated in the CATT study. CATT was a National Institute of Health/National Eye Institute study comparing Lucentis to Avastin. For more information about the CATT study, please visit www.nei.nih.gov/CATT
NORI participated in 1 large DME ranibizumab trial from 2007 until 2012
- FDA approved for treatment of DME August 2012
- Remains the ONLY FDA approved medication for the treatment of DME
NORI participated in 3 large Macular Edema/RVO ranibizumab trials from 2007 until 2012
- FDA approved for treatment of Macular Edema associated with RVO in June 2010.
Macugen
- FDA approved for Wet AMD December 2004
- First FDA approved Anti-VEGF
- NORI participated in 2 Wet AMD pegaptanib trials in 2005 & 2006
